secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001558370-22-017922
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma appoints Christopher Brooke as COO, effective Nov 14, 2022
-------------------------------------------------------------------------

- Christopher Brooke previously served as EVP Rare Disease Development since April 2021.
- Brooke holds a 47.5% ownership interest in Rumpus, from which Aytu acquired enzastaurin license.
- Aytu paid $4.0M in milestones to Rumpus in fiscal 2022 ($2.6M cash + 2,188,940 shares).
- Brooke has over 20 years healthcare management experience at Johnson & Johnson, AstraZeneca, and AmerisourceBergen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022017922/0001558370-22-017922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022017922/aytu-20221115x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer